Cargando…
DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines
Autores principales: | Zhao, Ya-Hui, Jiang, Wei, Gao, Hai, Pang, Guo-Zheng, Wu, Yu-Shuang, Wang, Yuan-Xian, Sheng, Meng-Yao, Xie, Jia-Ying, Wu, Wan-Ling, Ji, Zhi-Jian, Du, Ya-Rui, Zhang, Lei, Wang, Xiao-Qin, Walsh, Colum P, Jiang, Hai, Xu, Guo-Liang, Zhou, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305735/ https://www.ncbi.nlm.nih.gov/pubmed/37378658 http://dx.doi.org/10.1093/procel/pwac028 |
Ejemplares similares
-
Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma
por: Hu, Huimin, et al.
Publicado: (2017) -
Reactivity-dependent profiling of RNA 5-methylcytidine dioxygenases
por: Arguello, A. Emilia, et al.
Publicado: (2022) -
Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD
por: Wu, Chao, et al.
Publicado: (2019) -
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021) -
Transition of Dephospho-DctD to the Transcriptionally Active State via Interaction with Dephospho-IIA(Glc)
por: Kang, Sebin, et al.
Publicado: (2022)